<i>Conclusions:</i> While promising advances in gene therapy for GJB2-related HL have been achieved in preclinical studies, significant scientific, technical, and ethical barriers must be addressed before clinical application, especially during embryogenesis. This evidence concerns the gene GJB2 and Hodgkins lymphoma.